Use of Takhzyro (lanadelumab) for at least six months led to fewer hereditary angioedema (HAE) attacks and treated…
Articles by Forest Ray PhD
The U.S. Food and Drug Administration (FDA) has approved a new convenience administration kit for people using Berinert, an…
Effective management of hereditary angioedema (HAE) should include addressing psychological and mental health, given that depression, stress, and anxiety…
The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing approval to BioCryst Pharmaceuticals’ Orladeyo (berotralstat),…
Japan’s National Health Insurance System (NHI) has approved the addition of Orladeyo (berotralstat), an oral preventive treatment for…
Newer preventive therapies for hereditary angioedema (HAE) lead to a better quality of life and fewer attacks than on-demand…
Orladeyo (berotralstat) — an oral therapy developed by BioCryst Pharmaceuticals to prevent swelling attacks in people with hereditary angioedema…
The first patient has been dosed in RAPIDe-1, a Phase 2 trial of PHVS416, an oral on-demand treatment being…
Using oral KVD900 as an on-demand treatment for hereditary angioedema (HAE) attacks is safe and significantly reduces both…
A new generic form of icatibant injection is now available in the United States to treat acute attacks of…